Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Niagen BioscienceNAGE +3.76%68 Median PS Value is $7.69 as of Aug. 19, 2026, which is 968% above its 10-year median of 0.72. GuruFocus rates NAGE with a GF Score™ of 68/100 and a GF Value™ of $4.94 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 278 Biotechnology companies, Niagen Bioscience ranks better than 71.22% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Niagen Bioscience (NAS:NAGE) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Niagen Bioscience's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
3.165
/
7.69
=
0.41
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niagen Bioscience Median PS Value Related Terms
Niagen Bioscience Median PS Value Historical Data
* Premium members only.
The historical data trend for Niagen Bioscience's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NAGE vs LCTX, IFRX, VRXA: Median PS Value Comparison
For the Biotechnology subindustry, Niagen Bioscience's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Niagen Bioscience Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Niagen Bioscience's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Niagen Bioscience's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 5.0526.
Niagen Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.522.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niagen Bioscience (NAGE) has a Median PS Value of $7.69 as of Aug. 19, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Niagen Bioscience and its competitors. This is 968% above median its historical median of 0.72. Over the past decade, Niagen Bioscience's Median PS Value has ranged from 0.18 to 1.83. According to the industry distribution chart, Niagen Bioscience ranks #80 out of 278 companies in the Biotechnology industry, placing it in the top 28.8%.
Is Niagen Bioscience's Median PS Value too high?
Niagen Bioscience's current Median PS Value of $7.69 is 968% above median its 10-year median of 0.72. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 1.83. The Biotechnology industry median Median PS Value is 0.62. Niagen Bioscience's value of $7.69 is 1140.3% above this industry median. Based on the distribution chart, Niagen Bioscience ranks #80 out of 278 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Niagen Bioscience has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's Median PS Value compare to LCTX and IFRX?
According to the Biotechnology industry distribution chart, Niagen Bioscience ranks #80 out of 278 companies for Median PS Value. This puts Niagen Bioscience in the upper half of its industry. The industry median Median PS Value is 0.62. Niagen Bioscience's value of $7.69 is 1140.3% above this benchmark. Historically, Niagen Bioscience's own Median PS Value has ranged from 0.18 to 1.83 over the past decade. While the company's 10-year median is 0.72 vs. the industry median of 0.62, Niagen Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Niagen Bioscience's current Median PS Value of $7.69 is 1140.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Niagen Bioscience and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Niagen Bioscience's current Median PS Value is $7.69, which is 968% above median its own 10-year median of 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Niagen Bioscience (NAGE) is currently considered Possible Value Trap. The stock's GF Value™ is $4.94, compared to a current price of $3.17 — trading 35.9% below its estimated fair value. The current Median PS Value is $7.69, which is 968% above median its 10-year median of 0.72 and 1140.3% above the Biotechnology industry median of 0.62. Niagen Bioscience's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Niagen Bioscience (NAGE), the current Median PS Value is $7.69 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Niagen Bioscience (NAGE) Overvalued in 2026?
Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued.
The current stock price of $3.17 is trading 35.9% below its estimated GF Value™ of $4.94.
GuruFocus considers Niagen Bioscience to be Possible Value Trap.
Key valuation signals for NAGE:
Median PS Value: $7.69 (968% above median its 10-year median of 0.72)
GF Value™: $4.94 vs. price of $3.17 (35.9% below fair value)
Industry Position: 1140.3% above the Biotechnology median (#80 of 278)
No single metric tells the full story. See the NAGE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
68GF Score
Get the complete analysis for NAGE
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAGE has been successfully added to your 
